R
enal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies and close to 90% of all renal neoplasms (Jemal, Siegel, Xu, & Ward, 2010) . Renal cell carcinomas, by definition, are tumors that originate in the renal cortex. These tumors are often asymptomatic, have diverse clinical manifestations, and can be associated with hereditary syndromes. Surgery is the treatment of choice for localized RCC. In recent years, there has been a shift from radical nephrectomy toward more nephron-sparing approaches. RCC still remains a predominantly surgical disease because RCCs are frequently characterized as tumors that are resistant to chemotherapy and radiation. However, advances in the treatment of metastatic RCC have evolved, primarily with biologic response modifiers.
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Incidence
The incidence of RCC is increasing in the United States (Lynch, West, Davila & Platz, 2007) . The incidence of RCC is slightly higher among African Americans than the Caucasian population. In 2011, there were approximately 60,920 new cases of kidney cancer reported in the United States (37,120 males and 23,800 females), which resulted in about 13,120 deaths (8,270 males and 4,850 females) (Amer ican Cancer Society, n.d.). RCC incidence rates increased steadily between 1975 and 1995, by 2.3% annually among Caucasian men, 3.1% among Caucasian women, 3.9% among African-American men, and 4.3% among AfricanAmerican women (Chow, Devesa, Warren, & Fraumeni, 1999) . Since then, the annual incidence rate has steadily increased by 2.6% (National Cancer Institute [NCI], 2011) .
A likely cause for the increase in the incidence of RCC is the widespread use of abdominal imaging in the last 15 to 20 years. Pantuck, Zisman, and Belldegrun (2001) commented that less than 10% of RCCs were detected incidentally in the 1970s compared to the over 60% detected incidentally in 1998. The historical classic triad of flank pain, hematuria, and abdominal mass is seen infrequently because many patients are being diagnosed incidentally (Jayson & Sanders, 1998) . Symptoms, if present, may be the result of local tumor growth, hemorrhage, metastatic disease, or paraneoplastic syndromes found in 20% of patients with RCC, with the most common being hypertension, polycythemia, and hypercalcemia (Gold, Fefer, & Thompson 1996; Sufrin, Chasan, Golio, & Murphy 1989) .
Etiology
RCC occurs in sporadic (nonhereditary) and hereditary forms. Even though hereditary RCCs only consist of 3% to 5% of all RCCs, more syndromes are now being described. These syndromes have proven to be valuable in the development of targeted therapies for the treatment of all types of RCC (Zbar et al., 2007) . RCC has been associated with hereditary and non-hereditary risk factors. These risk factors are described in Table 1 .
Genetics of Renal Cell Carcinoma
Kidney cancer is not a single disease but is composed of a number of different types of cancer that occur in the kidney, each caused by a different gene with a different histology (Linehan, Srinivasan, & Schmidt, 2010) .
There are several known kidney cancer genes: von HipppelLindau (VHL), met proto-oncogene (hepatocyte growth factor receptor) (MET), folliculin (FLCN), Treacher Collins syndrome 1 (TSC1), Treacher Collins syndrome 2 (TSC2), fumarate hydratase (FH), succinate dehydrogenase (SDH), and protein polybromo-1 (PB1) also known as BRG1-associated factor 180 (BAF180) (PBRM1) (see Table 2 ) (Varela et al., 2011) .
Classification, Grading, and Staging
Recent advancements in the understanding of the genetics of RCC have led to a new pathological classification of five different (Campbell & Lane, 2012; Kennedy et al., 1990) . The grading of RCC is based on the morphology of a neoplasm with hematoxylin and eosin (H&E) staining on microscopy. The most popular and widely used system for grading RCC is a nuclear grading system described by Fuhrman, Lasky, and Limas in 1982 . This system categorizes RCC into one of four grades based on nuclear characteristics and has been shown to correlate with prognosis (see Table 3 ).
The Tumor Node Metastasis (TNM) staging system is used for staging all histologic variants of renal carcinoma. This system assesses the anatomic extent of disease and has been shown to correlate with prognosis. A revision was proposed in 2010 and is supported by the American Joint Committee on Cancer (AJCC) (2010) (see Table 4 ).
Another commonly used staging system ranges from Stage I to IV based on anatomic stage and places into a prognostic group (see Table 5 ). It is hoped that with greater knowledge of tumor genetics and immunohistochemistry, there will be an 
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improved ability to make prognoses and appropriately target therapy to those who would most benefit (Odonez & Hank, 2011) .
Evaluation
High-quality computed tomography (CT) scan both prior to and following administration of intravenous contrast remains the radiologic modality for choice to work up a renal mass. Magnetic resonance imaging (MRI) may be useful in the setting of locally advanced disease, venous involvement, renal insufficiency, or allergy to IV contrast. However, due to concerns related to a potential link between nephrogenic systemic fibrosis (NSF) and gadolinium exposure, routine use of MRI is not advocated, and MRI should be reserved for patients who have had a previous allergic reaction to contrast (American Urological Association [AUA], 2009). Color flow Doppler imaging may be useful in detecting renal vein/vena cava involvement. Metastatic evaluation includes CT of the abdomen and pelvis, chest X-ray, and liver function tests. If chest xray is abnormal, then a CT of the chest is warranted. Bone scan should be ordered if there is an elevation of alkaline phosphatase and/or bone pain (Seaman, Goluboff, Ross, & Sawczuk, 1996) .
The role of biopsy for localized renal tumor has evolved. Initially, renal biopsy was believed to offer no significant benefit except in patients with metastases in which a diagnosis was needed. However, more recently, the role of renal biopsy has been re-examined. This is supported by the fact that about 20% of clinical Stage 1 renal masses may be benign, and improvements in accuracy and safety of biopsy, related to better CT and MRI-guided techniques, have resulted in a reconsideration of the role of biopsy (Kummerlin et al., 2008; Lane et al., 2007; Lebret et al., 2007; Oda et al., 2001; Pahernik, Ziegler, Roos, Melchior, & Thuroff, 2007; Remzi et al., 2006; Salamanca et al., 2007; Schmidbauer et al., 2008; Somani et al., 2007; Volpe et al., 2007; Zagoria, Gasser, Leyendecker, Bechtold, & Dyer, 2007) . In a review of the pathology and radiology databases of a single tertiary referral from 2000 to 2009, Ramsey and colleagues (2010) suggested that renal biopsy is no longer simply for diagnostic dilemmas in patients with renal masses. Older adult patients under consideration for targeted therapies and unfit for cytoreductive nephrectomy have established a role for renal biopsy in confirming the diagnosis prior to treatment (Ramsey et al., 2010) .
Treatment Modalities
The treatment options for RCC are surgery, radiation therapy (palliative), targeted therapy (bevacizumab, sumitinib, sorafenib, everolimus, temsirolimus), biological therapy (immunotherapy), and combinations of these (Campbell & Lane, 2012) . Surgical resection can be curative in patients who present with localized RCC. Unfortunately, most RCCs are asymptomatic for most of their natural history. Therefore, the diagnosis is frequently made when the disease has progressed locally to the extent where it cannot be resected or has already metastasized.
Historically, radical nephrectomy (removal of kidney, ipsilateral adrenal gland, and Gerota's fascia) was advocated for the surgical treatment of RCC. Nephronsparing surgery was indicated for those with a solitary kidney, those at risk for inheritable forms of RCC (such as VHL), or patients with baseline or at risk for renal insufficiency (such as with diabetes mellitus). However, the current trend is to consider nephron-sparing surgical procedures when the lesion is amenable.
The role of adrenalectomy at the time of nephrectomy has also been questioned. In a review of 351 patients who underwent radical nephrectomy from 1998 to 2008, Tsui et al. (2000) concluded that adrenal involvement is not likely with localized early stage RCC, and thus, adrenalectomy is not necessary, particularly when the CT scan is negative. In patients with large and upper pole tumors, the risk of adrenal involvement is greater, and ipsilateral adrenalectomy should be performed; all 10 patients with ipsilateral adrenal metastases in the aforementioned review had upper pole tumors (8) and/or large renal masses (2) (Tsui et al., 2000) .
For patients with Stage I or Stage II disease, surgery is usually curative. Surgical options include either a radical or partial nephrectomy for T1 (≤ 7 cm) lesions. Recently, there has been a paradigm shift in the treatment of such tumors from radical nephrectomies to more nephronsparing approaches. Numerous studies have shown that patients who have small tumors (< 4 cm) with a healthy contralateral kid- 
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ney treated with partial nephrectomy will have much higher likelihood of maintaining an acceptable glomerular filtration rate (GFR) over 45 ml/minute when compared to radical nephrectomy patients (36% vs. 5%) (Huang et al., 2006) . Survival was better for patients undergoing partial nephrectomy compared to patients treated with radical nephrectomy (85% vs. 78%) for tumors between 4 to 7 cm (p = 0.01). This increased survival is likely attributable to better renal function in patients with partial nephrectomy (Weight et al., 2010) .
Other nephron-sparing approaches, such as radiofrequency ablation, cryoablation, and even active surveillance, may be acceptable alternatives to radical nephrectomy for carefully selected patients who are compliant with regular follow-up visits. For patients with Stage III (> 7 cm) primary lesions, however, radical nephrectomy is the standard of care. Guidelines developed by an AUA panel exist for the management of the clinical Stage 1 renal mass (AUA, 2009).
Laparoscopic nephrectomy, hand-assisted laparoscopic nephrec tomy, and robotic-assisted nephrectomy are less invasive procedures than the traditional open radical nephrectomy and are reasonable alternatives to open radical nephrectomy in T1 and T2 tumors. These procedures incur less morbidity, and are associated with less blood loss and a shorter recovery time (Burgess et al., 2007) . Disadvantages include higher costs along with the technically demanding aspect of these procedures. Partial nephrectomy is traditionally performed in an open fashion. However, in an attempt to decrease the associated morbidity, this surgery is increasingly being performed laparoscopically or with robotic-assisted laparoscopy by skilled surgeons.
Patients faced with treatment choices regarding management of RCC look to the urologist and urology staff for guidance in selecting the most appropriate treatment. The patient and his or her family may have questions after the initial office visit that can often be addressed in a timely fashion by a knowledgeable nurse. This often decreases the patient's anxiety and allows the patient to further understand recommendations made by the urologist. Informed choice is important, and nursing staff play a critical role in ensuring that the patient understands the information being presented and the risks and benefits of the treatment selected.
Treatment Options for Stage IV Disease
The value of nephrectomy in metastatic RCC has long been debated. For Stage IV disease, surgery may be considered in carefully selected patients. Cytoreductive nephrectomy can be considered for palliation of local symptoms before initiating systemic immunotherapy. Two welldesigned randomized-controlled trials comparing immuno therapy alone versus immuno therapy and radical nephrectomy showed increased survival in the combined group (Flanigan et al., 2001; Mickisch, Garin, von Poppel, de Prijck, & Sylvester, 2001) . Reports have documented regression of metastatic RCC after removal of the primary tumor; however, this is extremely uncommon (Marcus et al., 1993) .
Removal of a solitary metastasis is indicated in select patients with good overall performance status. A retrospective analysis from a single institution revealed improved cancer-specific survival advantage, even with removal of more than one metastatic lesion. The authors also reported increased risk of death due to RCC in patients who did not undergo surgical resection of metastasis (Alt et al., 2011) . This area is still under great debate, and more studies are needed.
Paraneoplastic syndromes in RCC include hypercalcemia, polycythemia, galactorrhea, anemia, nonmetastatic hepatic dysfunction (Stauffer's syndrome), hypertension, Cushing's syndrome, altered glucose metabolism, amyloidosis, neuromyopathies, vasculopathies, nephropathies, and prostaglandin elevation (Palapattu, Kristo, & Rajfer, 2002) . Palliative nephrectomy can be considered in patients with metastatic disease for alleviation of symptoms, such as pain, hemorrhage, malaise, hypercalcemia, erythrocytosis, or hypertension, but many clinicians believe most symptoms can be treated medically without surgical intervention.
Biological therapies include interferons, interleukins, colonystimulating factors, monoclonal antibodies, vaccine gene therapy, and non-specific immunomodulators. Interferons are natural glycoproteins with antiviral, antiproliferative, and immunomodulatory properties. Interleukin-2 (IL-2) is a T-cell growth factor and activator of T cells, as well as a natural killer cell. IL-2 affects tumor growth by activating lymphoid cells in vivo without directly affecting tumor proliferation. Interferons and interleukins are cytokines with low response rates (5% to 20%); a median overall survival is approximately 12 months (Fisher, Rosenberg, & Fyfe, 2000; Janzen, Kim, Figlin, & Belldegrun, 2003; McDermott et al., 2005) .
Immunomodulators, such as lenalidomide, a derivative of thalidomide, inhibits vascular endo thelial growth factor (VEGF), stimulates T and natural killer cells and inhibits inflammatory cytokines. Currently in phase 2 trials, this drug showed an antitumor effect in selective cases (Choueiri et al., 2006; Patel et al., 2008) . Vaccine trials are still being developed, and autologous vaccine therapy is now being Notes: AE = adverse events, CYP3A4 = cytochrome P4503A4, DDi = drug-drug interactions, LV = left ventricle, mRCC = metastatic renal cell carcinoma, PBO = placebo, Rx = treatment, qd = daily, BID = twice a day, QOD = every other day, NV = nausea/vomiting, GI = gastrointestional, HTN = hypertension.
Source: Adapted from Ellsworth, 2011. 
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Notes: AE = adverse events, CYP3A4 = cytochrome P4503A4, DDi = drug-drug interactions, LV = left ventricle, mRCC = metastatic renal cell carcinoma, PBO = placebo, Rx = treatment, qd = daily, BID = twice a day, QOD = every other day, NV = nausea/vomiting, GI = gastrointestional, HTN = hypertension.
Source: Adapted from Ellsworth, 2011. More recent developments have focused on targeted cancer therapies (see Table 6 ). Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules involved in tumor growth and progression (everolimus, sorafenib tosylate, sunitinib maleate, temsirolimus). Pazopanib (Votrient ® ) is an oral medication that interferes with angiogenesis. It is a kinase inhibitor indicated for treatment of patients with advanced RCC (Kidney Cancer Assoication, 2012) . Several targeted therapies have been approved for the treatment of metastatic RCC. One newer form of therapy under investigation is low intensity stem cell transplantation with multiple lymphocyte infusions to treat advanced RCC (NCI, 2012) .
Although these therapies are more commonly administered by oncologists, an awareness of these agents by nursing staff and urologists is helpful. Patients with advanced disease are often followed by both urologists and oncologists, and an understanding of the indications and contraindications for use, as well as method of administration and potential adverse effects, may allow urologists and nurses to alleviate some anxieties of patients with metastatic and/or unresectable disease. Urologists and their nursing staff can also provide these patients with basic information that will better prepare the patient for his or her meeting with the oncologist. Finaly, since management of advanced RCC involves a multidisciplinary approach, questions pertinent to therapy may arise in the urologist's office, and thus, an awareness of these agents may allow the urologist and/or urology nurse to address some of the patient's questions.
Summary
RCC is a common malignancy with an incidence that has risen over the last 30 years largely due to incidental findings on imaging. During this time, the evaluation and management of RCC has evolved due to a greater understanding of the genetics of the disease, changes in the TNM staging system, and a trend to less invasive and organ-sparing surgical treatments. Minimally invasive procedures will continue to be at the forefront of treatment in the decades to come.
With the advent of biologic response modifiers, additional therapies are now available for patients with metastatic RCC. Nurses and physicians caring for patients with RCC must be knowledgeable about these newer treatment modalities, which patients are appropriate candidates for such therapies, anticipated response rates, and the management of potential adverse effects. A multidisciplinary approach, which includes nurses and allied personnel, will continue to be vital in the management of these patients.
